Protective effects of combining human umbilical cord mesenchymal stem cells and glucagon like peptide-1 receptor agonist on the islet inflammatory injury in rat model of type 2 diabetes mellitus

VernacularTitle:脐带间充质干细胞联合利拉鲁肽对2型糖尿病大鼠模型胰腺炎症损伤的保护作用
Author: Pin CHEN ; Shan HUANG ; Daifen WEN ; Lianghu HUANG ; Zhulin SHAO ; Xiangjin XU ; Qin HUANG
Keywords: Diabetes mellitus,type 2; Liraglutide; Mesenchymal stem cells; Islet function; TLR4/NF-κB pathway
From: Chinese Journal of Endocrinology and Metabolism 2016;32(12):1003-1009
CountryChina
Language:Chinese
Abstract: T2DM+LIRA group and T2DM+LIRA+UC-MSCs group (P<0. 05). The ratio of insulin positive area in pancreas tissue was obviously rised, while the ratio of glucagon positive area in pancreas tissue was clearly descended in T2DM+LIRA+UC-MSCs group. And the same difference in valuating islet cells apoptosis by TUNEL could be observed ( P<0. 05). The expression of NF-κB and TLR4 protein in pancreas tissue of T2DM+LIRA+UC-MSCs group were the least amongthefourgroups[(0.75±0.10)vs(0.60±0.08),(0.47±0.08),(0.31±0.04),P<0.05]and[(1.24± 0. 12) vs (0. 93 ± 0. 10), (0. 95 ± 0. 09), (0. 74 ± 0. 07), P<0. 05 ]. Conclusion The combined treatment of liraglutide with umbilical cord mesenchymal stem cells is superior over a single treatment of liraglutide or umbilical cord mesenchymal stem cells in improving the islet function in type 2 diabetes mellitus models, which may be related to the down modulating the TLR4/NF-κB inflammatory signaling pathway.